The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial
Abstract
Background— Most cardiovascular events associated with hypertension are complications of atherosclerosis. Some antihypertensive agents influence experimental models of atherosclerosis through mechanisms independent of blood pressure lowering. Methods and Results— The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind trial in 2334 patients with hypertension that compared the effects of a 4-year treatment based on either lacidipine or atenolol on an index of carotid atherosclerosis, the mean of the maximum intima-media thicknesses (IMT) in far walls of common carotids and bifurcations (CBM max ). This index has been shown by epidemiological studies to be predictive of cardiovascular events. A significant ( P <0.0001) effect of lacidipine was found compared with atenolol, with a treatment difference in 4-year CBM max progression of −0.0227 mm (intention-to-treat population) and −0.0281 mm (completers). The yearly IMT progression rate was 0.0145 mm/y in atenolol-treated and 0.0087 mm/y in lacidipine-treated patients (completers, 40% reduction; P =0.0073). Patients with plaque progression were significantly less common, and patients with plaque regression were significantly more common in the lacidipine group. Clinic blood pressure reductions were identical with both treatments, but 24-hour ambulatory systolic/diastolic blood pressure changes were greater with atenolol (−10/−9 mm Hg) than with lacidipine (−7/−5 mm Hg). No significant difference between treatments was found in any cardiovascular events, although the relative risk for stroke, major cardiovascular events, and mortality showed a trend favoring lacidipine. Conclusion— The greater efficacy of lacidipine on carotid IMT progression and number of plaques per patient, despite a smaller ambulatory blood pressure reduction, indicates an antiatherosclerotic action of lacidipine independent of its antihypertensive action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
Cited by
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citationDahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328333146d · Cited by 1,643
Self-citationMazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Atenolol in hypertension: is it a wise choice?
Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17355-8 · Cited by 562
Blood Pressure Lowering Treatment Trialists' Collaboration (2013) · BMJ · doi:10.1136/bmj.f5680 · Cited by 263
Clinical Value of Ambulatory Blood Pressure: Evidence and Limits
Mancia, G., & Verdecchia, P. (2015) · Circulation Research · doi:10.1161/circresaha.116.303755 · Cited by 211
Self-citationSubgroup analyses in therapeutic cardiovascular clinical trials: Are most of them misleading?
Hernández, A. V., Boersma, E., Murray, G. D., Habbema, J. D. F., & Steyerberg, E. W. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.020 · Cited by 131
Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
Crouse, J. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600012-jlr200 · Cited by 66
Proietti, M., Raparelli, V., Laroche, C., Dan, G.-A., Janion, M., Popescu, R., Sinagra, G., Vijgen, J., Boriani, G., Maggioni, A. P., et al. (2017) · EP Europace · doi:10.1093/europace/euw169 · Cited by 58
Koppenaal, T., Linmans, J., Knottnerus, J. A., & Spigt, M. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.11.020 · Cited by 56
Limited reproducibility of MUCH and WUCH: evidence from the ELSA study
Mancia, G., Facchetti, R., Cuspidi, C., Bombelli, M., Corrao, G., & Grassi, G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz651 · Cited by 53
Self-citationLundy, A.-L. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3066 · Cited by 19
Metadata
- Authors
- Zanchetti, A., Bond, M. G., Hennig, M., Neiss, A., Mancia, G., Dal Palù, C., Hansson, L., Magnani, B., Rahn, K.-H., Reid, J. L., Rodicio, J., Safar, M., Eckes, L., & Rizzini, P.
- Venue
- Circulation
- Published
- 2002-11-05
- Volume
- 106
- Issue
- 19
- Pages
- 2422-2427
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2160258470
- Cited by
- 514
- References
- 1
- FWCI
- 25.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
